Galectin Therapeutics reported $-8597000 in Net Income for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Abbvie ABBV:US USD 3.95B 3.03B
Bristol Myers Squibb BMY:US USD 1.61B 185M
Galectin Therapeutics GALT:US USD -8597000 1.02M
Gilead Sciences GILD:US USD 1.79B 645M
Idera Pharmaceuticals IDRA:US USD -3099000 2.21M
Intercept Pharmaceuticals ICPT:US USD 267.45M 274.98M
Merk MRK:US USD 3.25B 696M
Regulus Therapeutics RGLS:US USD -7551000 293K
Vital Therapies VTL:US USD -21224000 677K
YTE INCY:US USD 112.78M 48.66M